HERG Screening Market Share

Global HERG Screening Market Overview

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

HERG Screening Market Trends

• Increase in prevalence of heart diseases is driving the market growth

As heart disease prevalence and the number of heart condition patients both rise, the market is expected to grow. The market is growing as a result of increased R&D activities in support of new product releases. Additionally, it is projected that a rise in the number of innovative drug entity approvals will support the market's growth. The market is growing as a result of both the creation of remedies for illnesses and disorders and the rise in demand for drug formulations. Growing challenges in producing biotechnological or pharmaceutical goods based on the application are also creating more opportunities for the growth of the HERG screening market.

Due to the growth in instances of cardiotoxicity, there has been a significant demand for screening the materials used in pharmaceutical production. Traditional testing methods may not always be better than HERG tests, but they may be safer and more successful when used on medications. Cardiovascular drugs are increasingly having adverse side effects in patients with pre-existing heart conditions. Cardiotoxicity is more common in patients who have had cancer treatment or cardiac surgery. Consequently, there is a rising demand for equipment and services that enable efficient cardiotoxicity testing. The heart has a harder time carrying out normal functions and distributing blood throughout the body when there is cardiotoxicity. Cardiotoxicity consequently increases the risk of cardiomyopathy, which reduces the heart's capacity to pump blood.

Heart disease is the top cause of death for both men and women worldwide. According to the American College of Cardiology, an American will experience a myocardial infarction every 40 seconds. Emergency medical services reported that 356,461 Americans had cardiac arrest outside of a hospital in 2017, and in 52% of those cases, emergency medical services treatment was started. Only 18.7% of the patients had ventricular fibrillation or ventricular tachycardia at the start of their treatment, which might have been shocked by an AED. 10.4% of adults survived after leaving the hospital, and 8.4% of them had satisfactory functional status.

Sedentary habits and common risk factors, such as hypertension (which can range from 28% in the United Arab Emirates to 41% in Libya and Morocco), diabetes (which can range from 4% in the Islamic Republic of Iran to 19% in Sudan), and hypercholesterolemia (which can range from 14% in Lebanon to 52% in the Islamic Republic of Iran), are to blame for the prevalence of cardiovascular diseases. The market for drug discovery will expand as a result of the rise in heart disease, boosting the expansion of the HERG screening industry.Thus, driving the HERG Screening market revenue.

HERG Screening Market Segment Insights

HERG Screening Type Insights

The HERG Screening market segmentation, based on Type, includes Gene KCNH2 and Mutant KCNH2. Gene KCNH2 segment dominated the market in 2022. This channel is especially important for the generation and transmission of electrical impulses as it is in charge of removing positively charged potassium atoms from the cells. This is so that it can move the atoms of potassium. The KCNH2 gene is in charge of controlling and supplying the necessary instructions for the production of potassium channels. The main reason causing the ultimate emergence of cardiac arrhythmia was the KCNH2 mutation.

HERG Screening Ion Channel Insights

The HERG Screening market segmentation, based on Ion Channel, includes Voltage Gated and Ligand Gated. Voltage Gated segment dominated the HERG Screening market in 2022.The members of the voltage-gated ion channel family that regulate the open and closed states of the cell membrane potential include Na+, Ca+, and K+. The ionic gradients required for regular cell activity are maintained by these channels in a variety of cell types, including neurons, heart muscle, and skeletal muscle. The movement of ions across cell membranes is tightly regulated by these channels.

HERG Screening Application Insights

 The HERG Screening market segmentation, based on Application, includes Antiarrhythmic, Antipsychotic, Antibiotics, and Others. Antiarrhythmic segment dominated the market in 2022. Antiarrhythmic medications are used to treat symptomatic tachycardias and premature beats. These can be administered intravenously in an emergency or orally for long-term treatment. These drugs either prevent aberrant pacemaker tissue firing or reduce the speed at which impulses are transmitted in tissues that conduct too quickly or engage in reentry. The use of these assays for arrhythmia treatment, scientific investigations into the safety and effectiveness of HERG screening, and an increase in cardiovascular diseases globally are all factors propelling the market's growth.

Figure 1: HERG Screening Market, by Application, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

HERG Screening Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America HERG Screening Market dominated this market in 2022 (45.80%). Every 40 seconds, a citizen of the United States will experience a myocardial infarction, according to the American College of Cardiology. In 2017, 356,460 Americans went through an out-of-hospital cardiac arrest, and in 52% of those cases, emergency medical services were called.Further, the U.S. HERG Screening market held the largest market share, and the Canada HERG Screening market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: HERG Screening Market Share By Region 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe HERG Screening market accounted for the healthy market share in 2022. Europe's western and eastern regions make up the majority of the market for HERG screening and are both regarded as major contributors.Further, the German HERG Screening market held the largest market share, and the U.K HERG Screening market was the fastest growing market in the European region.

The Asia Pacific HERG Screening market is expected to register significant growth from 2024 to 2032. A significant portion of the people in the area have chronic heart conditions, and the incidence of inflammatory disorders is rising quickly as well. Moreover, China’s HERG Screening market held the largest market share, and the Indian HERG Screening market was the fastest growing market in the Asia-Pacific region.

HERG Screening Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the HERG Screening market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, HERG Screening Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the HERG Screening Industry to benefit clients and increase the market sector. In recent years, the HERG Screening Industry has offered some of the most significant advantages to medicine. Major players in the HERG Screening market, including Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed, are attempting to increase market demand by investing in research and development operations.

Charles River Laboratories International Inc. (Charles River), a contract research organisation (CRO), provides essential products and services to speed up analysis, medication discovery, and development. It offers a variety of services for fundamental research, drug discovery, and safety assessment. The company also offers assistance with production, operations, and employment. It provides treatments for conditions affecting the cardiovascular, nervous, metabolic, inflammatory, pulmonary, musculoskeletal, and oncological systems. Charles River provides services to prestigious hospitals, universities, government agencies, pharmaceutical and biotechnology companies, and other clientele. The headquarters of Charles River are located in Wilmington, Massachusetts, a city in the US.

Analytical testing services are provided to clients in a variety of industries by a life sciences company called Eurofins Scientific SE (Eurofins). The company offers a variety of services including forensics, environmental testing, agroscience, biopharma, pharmaceutical discovery, early development, pharmaceutical central laboratory, biopharma product testing, and product testing. Its analytical methods help in figuring out whether biological products and chemicals are pure, real, and safe. It draws on its knowledge in logistics and information technology to offer a range of services. The company has activities in North America, South America, the Middle East, Asia Pacific, and Europe. Eurofins' main office is in Luxembourg. In July 2017, Eurofins Scientific purchased Discover X, a market leader in drug discovery technologies and services from target identification and lead discovery to preclinical and beyond.

Key Companies in the HERG Screening market include

• Charles River Laboratories


• Eurofins Scientific


• Merck KGaA


• Cyprotex Limited


• BSYS GmbH


• Creative bioarray


• Metrion biosciences


• Aurora Biomed

HERG Screening Industry Developments

March 2020: An alliance was formed between Charles River Laboratories and Deciphex, a pioneer in preclinical digital pathology software-as-a-service. The organisations will collaborate to co-develop deep learning-enabled technologies to facilitate expedited pathology analytics, and Charles River will serve as the sole contract research organisation providing the Patholytix preclinical solution to clients.

HERG Screening Market Segmentation

HERG Screening Type Outlook

• Gene KCNH2


• Mutant KCNH2

HERG Screening Ion Channel Outlook

• Voltage Gated


• Ligand Gated

HERG Screening Application Outlook

• Antiarrhythmic


• Antipsychotic


• Antibiotics


• Others

HERG Screening Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America